Search

A recent report from the Russian Academy of Sciences discusses the effects of gonadotropin-releasing hormone (GnRH) on the immune organs, such as the red bone marrow, thymus, spleen, and lymph nodes. The use of GnRH drugs leads to changes in these organs, including the replacement of red bone marrow with yellow marrow and an increase in lymphoid and myeloid progenitor cells. However, there is still limited understanding of the physiological mechanisms of immunomodulation in these conditions. Further research is needed to develop effective systems for immune control. [Extracted from the article]

The article reports on a study evaluating the efficacy of long-acting gonadotropin-releasing hormone analogues for managing central precocious puberty. Topics discussed include the comparative effectiveness of subcutaneous leuprolide acetate versus intramuscular leuprolide acetate, hormone suppression levels, and the potential for similar use in clinical practice.

A recent study conducted at King Edward Medical University in Lahore, Pakistan compared the effects of two different treatments on the volume reduction of uterine leiomyomas (fibroids) in premenopausal women. The study compared the use of a gonadotropin-releasing hormone agonist (leuprolide acetate) with an aromatase inhibitor (letrozole). The results showed that both treatments led to a reduction in fibroid volume, but there was no statistically significant difference between the two treatments. This research provides valuable information for medical professionals considering non-surgical treatments for uterine leiomyomas. [Extracted from the article]

A recent study conducted in Patras, Greece, explored the use of gonadotropin-releasing hormone agonists (GnRH-a) in improving pregnancy rates in women with endometriosis undergoing assisted reproduction techniques. The researchers conducted a literature review and found that while the regimen may have a positive clinical effect on severe cases of endometriosis, it is not routinely recommended to improve pregnancy rates. The study highlights the close relationship between endometriosis and infertility and the need for further research in this area. This information is relevant for obstetricians, gynecologists, and family physicians. [Extracted from the article]

A new report from the University of Chicago presents findings on the use of 5-alpha reductase inhibitors (5-ARIs) as an alternative to LHRH-agonists in the treatment of prostate cancer. The study found that men treated with 5-ARIs had better preservation of hormonal quality of life without negative effects on biochemical outcomes after 5 years of follow-up. This approach may be particularly beneficial for men at high risk of toxicities. The research suggests that using 5-ARIs in combination with radiation therapy can lead to improved preservation of quality of life and comparable disease outcomes to standard treatment. [Extracted from the article]

A recent study conducted at Sun Yat-sen University in Guangzhou, China, explored the effectiveness and safety of different dosage forms of gonadotropin-releasing hormone (GnRH) agonist in premenopausal hormone receptor-positive breast cancer patients. The study included 1109 patients who were treated with GnRH agonist plus selective estrogen receptor modulator or aromatase inhibitor. The results showed that both the 1-month and 3-month GnRH agonist regimens achieved more than 90% estradiol (E2) inhibition within 24 months, confirming the noninferiority of the 3-month regimen. The study concluded that the ovarian function suppression with the 3-month GnRH agonist was not inferior to that with the 1-month regimen, regardless of age or combination with other medications. [Extracted from the article]

A recent study from the University of Sao Paulo explores the use of personalized medicine in fertility preservation for patients undergoing cancer treatment. The study discusses various techniques, such as cryopreservation of oocytes and embryos, as well as the use of gonadotropin-releasing hormone (GnRH) agonists. The review highlights the challenges and controversies associated with these approaches, emphasizing the need for personalized treatment protocols and collaboration among healthcare professionals. The research calls for further refinement of these techniques to improve reproductive outcomes for patients facing fertility-impairing treatment. [Extracted from the article]

Kissei Pharmaceutical Co. Ltd. has been issued a patent for dosing regimens of a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis. Endometriosis is a gynecological condition characterized by the presence of endometrial-like tissue outside the uterus, which can cause infertility and various pain symptoms. The patent describes methods of dosing a patient with a GnRH antagonist based on the level of certain hormones in the patient's body, such as anti-Mullerian hormone (AMH) or b17-estradiol (E2). The invention aims to reduce endometriosis-associated pain without inducing hypo-estrogenic side effects. The patent also includes information on the compound represented by formula (II) and its administration. [Extracted from the article]

A recent study conducted by researchers at the University of Leuven in Belgium explored the effects of corticotropin-releasing hormone (CRH) on gastric electrical activity and sensorimotor function in healthy volunteers. The study found that peripheral CRH infusion accelerated gastric-emptying rate and increased postprandial gastric response, accompanied by a rise in symptoms. However, CRH did not alter gastric sensitivity or meal-induced accommodation. These findings suggest a significant link between stress and dyspeptic symptoms, with CRH playing a pivotal role in mediating these effects. [Extracted from the article]

This document provides information about a Phase 2 clinical trial for the drug Debio 4228, which is being studied as a treatment for prostate cancer. The trial aims to evaluate the safety and effectiveness of different doses of Debio 4228 administered through intramuscular injection. The trial is not yet recruiting participants and is expected to be completed in April 2026. The eligibility criteria for participants include having locally advanced/metastatic prostate cancer and being a candidate for continuous androgen deprivation therapy. The trial is being conducted by Debiopharm International SA. [Extracted from the article]

A recent study conducted by researchers at the University of Buenos Aires in Argentina has found that the drug valproate can decrease blood pressure in rats by affecting the DNA methylation and gene expression of the thyrotropin-releasing hormone (TRH) promoter. The study showed that valproate reduced TRH mRNA expression and increased DNA methylation in the SHR rat model of hypertension. Interestingly, these effects were also observed in the offspring of rats treated with valproate, suggesting a transgenerational inheritance of the blood pressure-lowering effects. This research provides insights into the role of epigenetic mechanisms in blood pressure regulation and inheritance. [Extracted from the article]

A recent report from Southwest Medical University discusses the impact of adjuvant gonadotropin-releasing hormone agonist (GnRH-a) on pregnancy outcomes in women with endometriosis following conservative surgery. The study analyzed 17 studies involving 2,485 patients and found that the use of GnRH-a after surgery resulted in a slightly higher pregnancy rate and a shorter time to conceive. However, there were no significant differences in other evaluated outcomes. The researchers suggest that incorporating adjuvant GnRH-a after conservative surgery may be beneficial for women with endometriosis, particularly before Assisted Reproductive Technology (ART), but further research is needed to confirm these potential advantages. [Extracted from the article]

A recent study conducted at Tel Aviv University aimed to determine if the follicular GnRH agonist challenge test (FACT) could predict suboptimal response to GnRH agonist trigger in non-medical oocyte cryopreservation cycles. The study included 91 women undergoing non-medical fertility preservation. The results showed that suboptimal response to agonist trigger, as assessed by post-trigger LH levels, was rare. The researchers concluded that FACT could be used as a tool to predict adequate LH levels elevation after agonist ovulation trigger, particularly in high responders. Further studies should focus on optimizing agonist trigger efficacy assessment and prediction. [Extracted from the article]

A recent study conducted by researchers at the University of Michigan explores the potential link between polycystic ovary syndrome (PCOS) and disruptions in gonadotropin-releasing hormone (GnRH) secretion patterns. The study focused on female mice that were prenatally androgenized (PNA) to mimic the neuroendocrine abnormalities observed in PCOS patients. The researchers found that PNA treatment and development altered the potassium currents in GnRH neurons, potentially contributing to differential neuron function before and after puberty, as well as in disease states such as PCOS. This research provides valuable insights into the underlying mechanisms of PCOS and may have implications for future treatments. [Extracted from the article]

A recent study conducted by researchers at Shandong University in China investigated the impact of hormone replacement therapy (HRT) on pregnancy outcomes in patients with a history of endometrial polyps (EPs) undergoing frozen-thawed embryo transfer (FET). The study included 395 women who underwent their first single euploid FET cycle and were divided into three groups based on endometrial preparation protocols. The results showed that there were no significant differences in live birth rates, miscarriage rates, ectopic pregnancy rates, premature live birth rates, or pregnancy complications among the three groups. The researchers concluded that gonadotropin-releasing hormone agonist combined with HRT did not improve pregnancy outcomes in patients with a history of EPs. [Extracted from the article]

A recent study conducted by researchers at the University of Leuven (KU Leuven) in Belgium explored the effects of corticotropin-releasing hormone (CRH) on gastric electrical activity and sensorimotor function in healthy volunteers. The study aimed to investigate the impact of peripheral CRH infusion on meal-related gastrointestinal symptoms, gastric motility, and sensitivity. The results showed that CRH exposure led to a decrease in gastric emptying half time and an increase in gastric amplitude, saliva cortisol levels, and postprandial symptom severity. However, there were no significant differences in discomfort thresholds, gastric compliance, and accommodation between CRH and placebo. This research contributes to our understanding of the role of CRH in gut-brain interactions and stress-related gastrointestinal disorders. [Extracted from the article]

A recent study conducted at the University of Genoa in Italy has provided new insights into gonadotropin therapy for fertility preservation in cancer patients. The study found that long-acting gonadotropin-releasing hormone agonist (GnRHa) was effective in inducing oocyte maturation, reducing the risk of ovarian hyperstimulation syndrome (OHSS), and suppressing ovarian function before chemotherapy. The researchers analyzed data from ovarian stimulation cases in oncological patients and found that the use of long-acting GnRHa resulted in a higher number of cryopreserved oocytes with a maturation rate of 80%. No cases of OHSS were observed with long-acting GnRHa triggering. These findings suggest that long-acting GnRHa could be a viable option for fertility preservation in cancer patients. [Extracted from the article]

A recent report from Boston Children's Hospital provides new insights into the treatment of adolescent endometriosis. The study examined the use of gonadotropin-releasing hormone agonists (GnRHa) plus add-back therapy in adolescents with laparoscopically confirmed endometriosis. The study found that almost half of the participants continued to use GnRHa with add-back therapy beyond the recommended 12-month duration. Additionally, the study found that treatment varied widely after discontinuation of GnRHa, with many participants returning to previously trialed medical therapies. This research provides valuable information for healthcare providers and patients in managing endometriosis in adolescents. [Extracted from the article]

A recent study conducted at the Asada Ladies Clinic in Nagoya, Japan, aimed to analyze the predictors and risk factors for empty follicle syndrome (EFS) in assisted reproductive technology (ART) with gonadotropin-releasing hormone (GnRH) agonist trigger. The study analyzed the GnRH test results of 3,765 patients from 2016 to 2018 and identified independent risk factors for EFS, including antral follicle count, basal LH levels, and the duration of ovarian stimulation. The study concluded that LH 30 min values of the GnRH test did not predict EFS. This research provides valuable insights into the risk factors associated with EFS in ART. [Extracted from the article]

A recent report discusses research conducted by the Guilan University of Medical Sciences on the effectiveness of different protocols for gonadotropin-releasing hormone (GnRH) agonists in achieving pregnancy outcomes. The study compared reduced dosages of long-acting GnRH agonists to short-acting GnRH agonists in 400 women. The researchers found that there were no significant differences in endometrial lining, oocyte numbers, fertilization rate, and embryo quality between the two groups. However, the long-acting protocol resulted in a lower percentage of ovarian hyperstimulation syndrome and was deemed superior to the short protocol. [Extracted from the article]

Anthracenes, Anthraquinones, Aromatic Polycyclic Hydrocarbons, Cancer, Drugs and Therapies, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Health and Medicine, Hormones, Hydrocarbons, Immunology, Immunosuppression, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Oncology, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Quinones Keywords: Anthracenes; Anthraquinones; Aromatic Polycyclic Hydrocarbons; Cancer; Drugs and Therapies; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Health and Medicine; Hormones; Hydrocarbons; Immunology; Immunosuppression; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Oncology; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Quinones EN Anthracenes Anthraquinones Aromatic Polycyclic Hydrocarbons Cancer Drugs and Therapies Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Health and Medicine Hormones Hydrocarbons Immunology Immunosuppression Nerve Tissue Proteins Neuropeptides Oligopeptides Oncology Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Quinones 1149 1149 1 10/30/23 20231030 NES 231030 2023 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New study results on cancer have been published. [Extracted from the article]

Keywords: Anemia; Bone Research; Business; Carboxylic Acids; Choline; Diet and Nutrition; Drugs and Therapies; Estradiol Congeners; Estradiol Therapy; Estrogens; Gonadal Hormones; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Gynecology; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hormone Antagonists; Hormone Replacement Therapy; Hormones; Hysterectomy; Kissei Pharmaceutical Co. Ltd.; Kissei Pharmaceutical Companies Ltd.; Menstruation; Micronutrient; Nerve Tissue Proteins; Neuropeptides; Norethindrone; Oligopeptides; Organic Chemicals; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceutical Companies; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Progestins; Sex Hormones; Surgery; Vaginal Agents; Vaginal Preparations; Women's Health EN Anemia Bone Research Business Carboxylic Acids Choline Diet and Nutrition Drugs and Therapies Estradiol Congeners Estradiol Therapy Estrogens Gonadal Hormones Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Gynecology Health and Medicine Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hormone Antagonists Hormone Replacement Therapy Hormones Hysterectomy Kissei Pharmaceutical Co. Ltd. Kissei Pharmaceutical Companies Ltd. Menstruation Micronutrient Nerve Tissue Proteins Neuropeptides Norethindrone Oligopeptides Organic Chemicals Peptide Hormones Peptide Proteins Peptides Pharmaceutical Companies Pharmaceuticals Pituitary Hormone-Releasing Hormones Progestins Sex Hormones Surgery Vaginal Agents Vaginal Preparations Women's Health 740 740 1 10/09/23 20231013 NES 231013 2023 OCT 12 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Kissei Pharmaceutical Co. Ltd. (Matsumoto, Japan) has been issued patent number 11759464, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]

Keywords: Anterior Pituitary Hormones; Cancer; Cervical Cancer; Cytology; Health and Medicine; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Oncology; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones; Proteins; Thyrotropin; Thyrotropin-Releasing Hormone; Women's Health EN Anterior Pituitary Hormones Cancer Cervical Cancer Cytology Health and Medicine Nerve Tissue Proteins Neuropeptides Oligopeptides Oncology Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones Proteins Thyrotropin Thyrotropin-Releasing Hormone Women's Health 1110 1110 1 10/09/23 20231013 NES 231013 2023 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on cervical cancer are presented in a new report. Keywords for this news article include: Chulalongkorn University, Bangkok, Thailand, Asia, Cytology, Oncology, Neuropeptides, Oligopeptides, Women's Health, Cervical Cancer, Peptide Hormones, Peptide Proteins, Health and Medicine, Nerve Tissue Proteins, Anterior Pituitary Hormones, Thyrotropin-Releasing Hormone, Pituitary Hormone-Releasing Hormones. Anterior Pituitary Hormones, Cancer, Cervical Cancer, Cytology, Health and Medicine, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Oncology, Peptide Hormones, Peptide Proteins, Peptides, Pituitary Hormone-Releasing Hormones, Proteins, Thyrotropin, Thyrotropin-Releasing Hormone, Women's Health. [Extracted from the article]

For more information on this research see: Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review. Keywords: Adnexal Diseases and Conditions; Drugs and Therapies; Gonadal Disorders; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Gynecology; Health and Medicine; Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Ovarian Diseases and Conditions; Ovarian Hyperstimulation Syndrome; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Risk and Prevention; Syndromes; Women's Health EN Adnexal Diseases and Conditions Drugs and Therapies Gonadal Disorders Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Gynecology Health and Medicine Hormones Nerve Tissue Proteins Neuropeptides Oligopeptides Ovarian Diseases and Conditions Ovarian Hyperstimulation Syndrome Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Risk and Prevention Syndromes Women's Health 675 675 1 09/19/23 20230922 NES 230922 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on ovarian hyperstimulation syndrome is now available. [Extracted from the article]

Keywords: Assisted Reproductive Techniques; Drugs and Therapies; Embryo Transfer; Endometriosis; Female Genital Diseases and Conditions; Female Urogenital Diseases and Conditions; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Health and Medicine; Hormone Replacement Therapy; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Reproductive Medicine; Uterine Diseases and Conditions; Women's Health EN Assisted Reproductive Techniques Drugs and Therapies Embryo Transfer Endometriosis Female Genital Diseases and Conditions Female Urogenital Diseases and Conditions Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Health and Medicine Hormone Replacement Therapy Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Reproductive Medicine Uterine Diseases and Conditions Women's Health 2898 2898 1 09/11/23 20230912 NES 230912 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on endometriosis. Assisted Reproductive Techniques, Drugs and Therapies, Embryo Transfer, Endometriosis, Female Genital Diseases and Conditions, Female Urogenital Diseases and Conditions, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Health and Medicine, Hormone Replacement Therapy, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Reproductive Medicine, Uterine Diseases and Conditions, Women's Health. [Extracted from the article]

Adnexal Diseases and Conditions, Corticotropin-Releasing Hormone, Corticotropin-Releasing Hormone Receptors, Endocrine System Diseases and Conditions, Female Urogenital Diseases and Conditions, G-Protein-Coupled Receptors, Genetics, Gonadal Disorders, Health and Medicine, Membrane Proteins, Nerve Tissue Proteins, Neuropeptide Receptors, Neuropeptides, Ovarian Cysts, Ovarian Diseases and Conditions, Peptide Hormones, Peptide Proteins, Pituitary Hormone-Regulating Hormone Receptors, Pituitary Hormone-Releasing Hormones, Polycystic Ovary Syndrome, Risk and Prevention, Syndromes, Women's Health Keywords for this news article include: French National Institute of Health and Medical Research (INSERM), Genetics, Ovarian Cysts, Women's Health, Peptide Hormones, Peptide Proteins, Gonadal Disorders, Membrane Proteins, Health and Medicine, Risk and Prevention, Nerve Tissue Proteins, Neuropeptide Receptors, Polycystic Ovary Syndrome, G-Protein-Coupled Receptors, Adnexal Diseases and Conditions, Ovarian Diseases and Conditions. [Extracted from the article]

Keywords: Assisted Reproductive Techniques; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Embryo Transfer; Endocrinology; Endometriosis; Estradiol Congeners; Estrogen; Female Genital Diseases and Conditions; Gonadal Hormones; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Gynecology; Health and Medicine; Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Reproductive Medicine; Uterine Diseases and Conditions; Women's Health EN Assisted Reproductive Techniques Clinical Research Clinical Trials and Studies Drugs and Therapies Embryo Transfer Endocrinology Endometriosis Estradiol Congeners Estrogen Female Genital Diseases and Conditions Gonadal Hormones Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Gynecology Health and Medicine Hormones Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Reproductive Medicine Uterine Diseases and Conditions Women's Health 1748 1748 1 08/21/23 20230822 NES 230822 2023 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New study results on endometriosis have been published. For more information on this research see: Pregnancy outcomes in women with adenomyosis, undergoing artificial endometrial preparation with and without gonadotropin-releasing hormone agonist pretreatment in frozen embryo transfer cycles: An RCT. [Extracted from the article]

Shandong, People's Republic of China, Asia, Combination Therapy, Contraceptives, Drugs and Therapies, Endometriosis, Female Genital Diseases and Conditions, Female Urogenital Diseases and Conditions, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Gynecology, Health and Medicine, Levonorgestrel, Levonorgestrel Therapy, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Progestins, Sex Hormones, Uterine Diseases and Conditions, Women's Health Keywords: Shandong; People's Republic of China; Asia; Combination Therapy; Contraceptives; Drugs and Therapies; Endometriosis; Female Genital Diseases and Conditions; Female Urogenital Diseases and Conditions; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Gynecology; Health and Medicine; Levonorgestrel; Levonorgestrel Therapy; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Progestins; Sex Hormones; Uterine Diseases and Conditions; Women's Health EN Shandong People's Republic of China Asia Combination Therapy Contraceptives Drugs and Therapies Endometriosis Female Genital Diseases and Conditions Female Urogenital Diseases and Conditions Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Gynecology Health and Medicine Levonorgestrel Levonorgestrel Therapy Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Progestins Sex Hormones Uterine Diseases and Conditions Women's Health 2263 2263 1 08/21/23 20230822 NES 230822 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on Uterine Diseases and Conditions - Endometriosis is now available. [Extracted from the article]

Adenomas, Breast Cancer, Cancer, Drugs and Therapies, Endocrine Research, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Health and Medicine, Macroadenoma, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Oncology, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Women's Health Keywords: Adenomas; Breast Cancer; Cancer; Drugs and Therapies; Endocrine Research; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Health and Medicine; Macroadenoma; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Oncology; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Women's Health EN Adenomas Breast Cancer Cancer Drugs and Therapies Endocrine Research Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Health and Medicine Macroadenoma Nerve Tissue Proteins Neuropeptides Oligopeptides Oncology Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Women's Health 59 59 1 07/17/23 20230717 NES 230717 2023 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on breast cancer. [Extracted from the article]

Anterior Pituitary Hormones, Biomarkers, Central Nervous System, Central Nervous System Diseases and Conditions, Diagnostics and Screening, Gonadotropin Releasing Hormones, Gonadotropins, Health and Medicine, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pituitary Hormone-Releasing Hormones, Spinal Cord, Spinal Cord Diseases and Conditions, Spinal Cord Injury, Growth Hormones Keywords: Anterior Pituitary Hormones; Biomarkers; Central Nervous System; Central Nervous System Diseases and Conditions; Diagnostics and Screening; Gonadotropin Releasing Hormones; Gonadotropins; Growth Hormones; Health and Medicine; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones; Spinal Cord; Spinal Cord Diseases and Conditions; Spinal Cord Injury EN Anterior Pituitary Hormones Biomarkers Central Nervous System Central Nervous System Diseases and Conditions Diagnostics and Screening Gonadotropin Releasing Hormones Gonadotropins Growth Hormones Health and Medicine Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones Spinal Cord Spinal Cord Diseases and Conditions Spinal Cord Injury 678 678 1 06/26/23 20230626 NES 230626 2023 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New study results on spinal cord injury have been published. [Extracted from the article]

Keywords: Bone Research; Cardiovascular Agents; Contraceptives; Diuretics; Dosage Forms; Drugs and Therapies; Endocrinology; Estradiol Congeners; Estradiol Therapy; Estrogen; Estrogens; Glycolates; Gonadal Hormones; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Health and Medicine; Hormone Antagonists; Hormone Replacement Therapy; Hormones; Hydroxy Acids; Hydroxypropyl Cellulose Therapy; Mannitol; Mannitol Therapy; Nerve Tissue Proteins; Neuropeptides; Norethindrone; Norethindrone Therapy; Oligopeptides; Patent Application; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Progesterone; Progestins; Risk and Prevention; Sex Hormones; Sugar Alcohols; Vaginal Agents; Vaginal Preparations; Women's Health EN Bone Research Cardiovascular Agents Contraceptives Diuretics Dosage Forms Drugs and Therapies Endocrinology Estradiol Congeners Estradiol Therapy Estrogen Estrogens Glycolates Gonadal Hormones Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Health and Medicine Hormone Antagonists Hormone Replacement Therapy Hormones Hydroxy Acids Hydroxypropyl Cellulose Therapy Mannitol Mannitol Therapy Nerve Tissue Proteins Neuropeptides Norethindrone Norethindrone Therapy Oligopeptides Patent Application Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Progesterone Progestins Risk and Prevention Sex Hormones Sugar Alcohols Vaginal Agents Vaginal Preparations Women's Health 3047 3047 1 06/19/23 20230620 NES 230620 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors ALONZO, David E. (Foster City, CA, US); ULLMER, Kathleen D. (San Mateo, CA, US); XIE, Minli (Belmont, CA, US), filed on November 28, 2022, was made available online on June 1, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. [Extracted from the article]

Anxiety, Anxiety Disorders, Corticotropin-Releasing Hormone, Gynecology, Health and Medicine, Mental Health Diseases and Conditions, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptide Proteins, Pituitary Hormone-Releasing Hormones, Women's Health Keywords: Anxiety; Anxiety Disorders; Corticotropin-Releasing Hormone; Gynecology; Health and Medicine; Mental Health Diseases and Conditions; Nerve Tissue Proteins; Neuropeptides; Peptide Hormones; Peptide Proteins; Pituitary Hormone-Releasing Hormones; Women's Health EN Anxiety Anxiety Disorders Corticotropin-Releasing Hormone Gynecology Health and Medicine Mental Health Diseases and Conditions Nerve Tissue Proteins Neuropeptides Peptide Hormones Peptide Proteins Pituitary Hormone-Releasing Hormones Women's Health 465 465 1 06/19/23 20230620 NES 230620 2023 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on anxiety disorders is now available. Keywords for this news article include: University of New South Wales Sydney, Gynecology, Neuropeptides, Women's Health, Peptide Hormones, Peptide Proteins, Anxiety Disorders, Health and Medicine, Nerve Tissue Proteins, Corticotropin-Releasing Hormone, Pituitary Hormone-Releasing Hormones, Mental Health Diseases and Conditions. [Extracted from the article]

Keywords for this news article include: Yale University School of Medicine, New Haven, Connecticut, United States, North and Central America, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Nerve Tissue Proteins, Gonadotropin Releasing Hormones, Pituitary Hormone-Releasing Hormones. Keywords: Gonadotropin Releasing Hormones; Gonadotropins; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones EN Gonadotropin Releasing Hormones Gonadotropins Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones 539 539 1 06/12/23 20230616 NES 230616 2023 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on pituitary hormone-releasing hormones is now available. Gonadotropin Releasing Hormones, Gonadotropins, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pituitary Hormone-Releasing Hormones. [Extracted from the article]

Endometriosis, Female Genital Diseases and Conditions, Female Infertility, Female Urogenital Diseases and Conditions, Gonadotropin Releasing Hormones, Gonadotropins, Health and Medicine, In Vitro Fertilization, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pituitary Hormone-Releasing Hormones, Reproductive Medicine, Uterine Diseases and Conditions, Women's Health Keywords: Endometriosis; Female Genital Diseases and Conditions; Female Infertility; Female Urogenital Diseases and Conditions; Gonadotropin Releasing Hormones; Gonadotropins; Health and Medicine; In Vitro Fertilization; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones; Reproductive Medicine; Uterine Diseases and Conditions; Women's Health EN Endometriosis Female Genital Diseases and Conditions Female Infertility Female Urogenital Diseases and Conditions Gonadotropin Releasing Hormones Gonadotropins Health and Medicine In Vitro Fertilization Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones Reproductive Medicine Uterine Diseases and Conditions Women's Health 294 294 1 05/22/23 20230526 NES 230526 2023 MAY 25 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on female infertility are discussed in a new report. [Extracted from the article]

Assisted Reproductive Techniques, Chorionic Gonadotropin, Chorionic Gonadotropin (hCG), Chorionic Gonadotropin Therapy, Clinical Research, Clinical Trials and Studies, Corpus Luteum Hormones, Drugs and Therapies, Drugs and Therapies - Chorionic Gonadotropin Therapy, Embryo Transfer, Gonadal Hormones, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Health and Medicine, Hormones, Hospitals, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Placental Hormones, Pregnancy Proteins, Progesterone, Progesterone Congeners, Reproductive Medicine, Reproductive Techniques, Sex Hormones, Single Embryo Transfer, Therapy, Women's Health. [Extracted from the article]

Keywords: Assisted Reproductive Techniques; Embryo Transfer; Endometriosis; Female Genital Diseases and Conditions; Female Urogenital Diseases and Conditions; Gonadotropin Releasing Hormones; Gonadotropins; Health and Medicine; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones; Reproductive Medicine; Uterine Diseases and Conditions; Women's Health EN Assisted Reproductive Techniques Embryo Transfer Endometriosis Female Genital Diseases and Conditions Female Urogenital Diseases and Conditions Gonadotropin Releasing Hormones Gonadotropins Health and Medicine Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones Reproductive Medicine Uterine Diseases and Conditions Women's Health 299 299 1 05/15/23 20230516 NES 230516 2023 MAY 18 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on endometriosis. For more information on this research see: Impact of adenomyosis and endometriosis on IVF/ICSI pregnancy outcome in patients undergoing gonadotropin-releasing hormone agonist treatment and frozen embryo transfer. [Extracted from the article]

Keywords: Shenyang; People's Republic of China; Asia; Breast Cancer; Cancer; Chemotherapy; Drugs and Therapies; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Gynecology; Health and Medicine; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Oncology; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Women's Health EN Shenyang People's Republic of China Asia Breast Cancer Cancer Chemotherapy Drugs and Therapies Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Gynecology Health and Medicine Nerve Tissue Proteins Neuropeptides Oligopeptides Oncology Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Women's Health 233 233 1 04/24/23 20230424 NES 230424 2023 APR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Oncology - Breast Cancer are discussed in a new report. Keywords for this news article include: Shenyang, People's Republic of China, Asia, Breast Cancer, Cancer, Chemotherapy, Drugs and Therapies, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Gynecology, Health and Medicine, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Oncology, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Women's Health, Department of Pharmacy. [Extracted from the article]

Keywords: Fujian; People's Republic of China; Asia; Brain; Central Nervous System; Diencephalon; Endocrine System Diseases and Conditions; Gonadotropin Releasing Hormones; Gonadotropins; Gynecology; Health and Medicine; Hypothalamus; Inflammation; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones; Polycystic Ovary Syndrome; Women's Health EN Fujian People's Republic of China Asia Brain Central Nervous System Diencephalon Endocrine System Diseases and Conditions Gonadotropin Releasing Hormones Gonadotropins Gynecology Health and Medicine Hypothalamus Inflammation Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones Polycystic Ovary Syndrome Women's Health 250 250 1 04/10/23 20230411 NES 230411 2023 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on Endocrine System Diseases and Conditions - Polycystic Ovary Syndrome are presented in a new report. Fujian, People's Republic of China, Asia, Brain, Central Nervous System, Diencephalon, Endocrine System Diseases and Conditions, Gonadotropin Releasing Hormones, Gonadotropins, Gynecology, Health and Medicine, Hypothalamus, Inflammation, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pituitary Hormone-Releasing Hormones, Polycystic Ovary Syndrome, Women's Health Keywords for this news article include: Fujian, People's Republic of China, Asia, Brain, Central Nervous System, Diencephalon, Endocrine System Diseases and Conditions, Gonadotropin Releasing Hormones, Gonadotropins, Gynecology, Health and Medicine, Hypothalamus, Inflammation, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pituitary Hormone-Releasing Hormones, Polycystic Ovary Syndrome, Women's Health, Fujian Normal University. [Extracted from the article]

Keywords for this news article include: First Affiliated Hospital of Zhengzhou University, Gynecology, Neuropeptides, Oligopeptides, Women's Health, Peptide Hormones, Peptide Proteins, Health and Medicine, Nerve Tissue Proteins, Gonadotropin Releasing Hormones, Pituitary Hormone-Releasing Hormones. Gonadotropin Releasing Hormones, Gonadotropins, Gynecology, Health and Medicine, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pituitary Hormone-Releasing Hormones, Women's Health Keywords: Gonadotropin Releasing Hormones; Gonadotropins; Gynecology; Health and Medicine; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones; Women's Health EN Gonadotropin Releasing Hormones Gonadotropins Gynecology Health and Medicine Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones Women's Health 151 151 1 04/03/23 20230404 NES 230404 2023 APR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in pituitary hormone-releasing hormones. [Extracted from the article]

Anterior Pituitary Hormones, Combination Therapy, Drugs and Therapies, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Growth Hormone, Growth Hormones, Health and Medicine, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones Keywords: Anterior Pituitary Hormones; Combination Therapy; Drugs and Therapies; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Growth Hormone; Growth Hormones; Health and Medicine; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones EN Anterior Pituitary Hormones Combination Therapy Drugs and Therapies Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Growth Hormone Growth Hormones Health and Medicine Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones 1416 1416 1 04/03/23 20230403 NES 230403 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on gonadotropin therapy. For more information on this research see: Efficacy and safety of a 4-year combination therapy of growth hormone and gonadotropin-releasing hormone analogue in pubertal girls with short predicted adult height. [Extracted from the article]

Keywords: Assisted Reproductive Techniques; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Embryo Transfer; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Health and Medicine; Hormone Replacement Therapy; Leiomyomas; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Reproductive Medicine EN Assisted Reproductive Techniques Clinical Research Clinical Trials and Studies Drugs and Therapies Embryo Transfer Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Health and Medicine Hormone Replacement Therapy Leiomyomas Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Reproductive Medicine 1240 1240 1 03/23/23 20230314 NES 230314 2023 MAR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on leiomyomas is now available. Assisted Reproductive Techniques, Clinical Research, Clinical Trials and Studies, Drugs and Therapies, Embryo Transfer, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Health and Medicine, Hormone Replacement Therapy, Leiomyomas, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Reproductive Medicine. [Extracted from the article]

Drugs and Therapies, Endometriosis, Female Genital Diseases and Conditions, Female Urogenital Diseases and Conditions, Gonadotropin Releasing Hormones, Gonadotropin Therapy, Gonadotropins, Health and Medicine, Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Pituitary Hormone-Releasing Hormones, Uterine Diseases and Conditions, Women's Health Keywords for this news article include: Medical University of Lublin, Lublin, Poland, Europe, Pharmaceuticals, Endometriosis, Neuropeptides, Oligopeptides, Women's Health, Peptide Hormones, Peptide Proteins, Drugs and Therapies, Health and Medicine, Hormone Antagonists, Gonadotropin Therapy, Nerve Tissue Proteins, Gonadotropin Releasing Hormones, Uterine Diseases and Conditions, Pituitary Hormone-Releasing Hormones. Keywords: Drugs and Therapies; Endometriosis; Female Genital Diseases and Conditions; Female Urogenital Diseases and Conditions; Gonadotropin Releasing Hormones; Gonadotropin Therapy; Gonadotropins; Health and Medicine; Hormone Antagonists; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pituitary Hormone-Releasing Hormones; Uterine Diseases and Conditions; Women's Health EN Drugs and Therapies Endometriosis Female Genital Diseases and Conditions Female Urogenital Diseases and Conditions Gonadotropin Releasing Hormones Gonadotropin Therapy Gonadotropins Health and Medicine Hormone Antagonists Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pituitary Hormone-Releasing Hormones Uterine Diseases and Conditions Women's Health 2023 MAR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on endometriosis. [Extracted from the article]

Studies from Peking University People's Hospital Add New Findings in the Area of Pituitary Hormone-Releasing Hormones (Serum levels of anti-Mullerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist...) For more information on this research see: Serum levels of anti-Mullerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study. Keywords: Anti-Mullerian Hormone; Clinical Research; Clinical Trials and Studies; Gonadotropin Releasing Hormones; Gonadotropins; Gynecology; Health and Medicine; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pituitary Hormone-Releasing Hormones; Testicular Hormones; Women's Health EN Anti-Mullerian Hormone Clinical Research Clinical Trials and Studies Gonadotropin Releasing Hormones Gonadotropins Gynecology Health and Medicine Nerve Tissue Proteins Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pituitary Hormone-Releasing Hormones Testicular Hormones Women's Health 2023 FEB 27 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on pituitary hormone-releasing hormones is now available. [Extracted from the article]